Neurocrine Biosciences Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Annual Valbenazine Revenue Outlook. It Also Authorized $300 Million Stock Buyback.
Neurocrine Biosciences Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results and Raised Annual Valbenazine Revenue Outlook. It Also Authorized $300 Million Stock Buyback.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated